Please login to the form below

Not currently logged in
Email:
Password:

MRC Technology and Peptinnovate join on bone disease

Firms aim to discovery a therapy using natural peptides 

Pharmaceutical research and developmentIndependent medical research charity MRC Technology has teamed up with Peptinnovate to assess potential therapies in bone diseases.

Peptinnovate, which is developing first-in-class disease modifying medicines for immuno-inflammatory diseases, will investigate its unique peptides derived from the bacterium mycobacterium tuberculosis, the pathogen that causes TB.

Natural peptides from the pathogen are able to modify the immunological and inflammatory response in humans. Peptinnovate is investigating whether the properties could form the basis of new medicines for a variety of disease indications that involve altered immune responses.

Andrew Lightfoot, CEO, Peptinnovate, said: “We are delighted to be working with experts at MRC Technology to better understand the potential of our approach in the treatment of bone diseases, our second area of therapeutic focus. 

“Peptinnovate is continuing to develop strongly, following on from our recent Biomedical Catalyst funding success, which stands us in good stead for future fundraising and partnering.”

The collaboration is a result of interaction by Stevenage Bioscience Catalyst, where Peptinnovate is based and MRC Technology is relocating next year.

Martino Picardo, CEO at Stevenage Bioscience Catalyst, added: “This partnership is just the kind of interaction Stevenage Bioscience Catalyst was established to facilitate and drive. 

“It's great to see this collaboration between one of our first and one of our newest tenants, and we hope to see many more fruitful relationships as the campus continues its rapid development.”

Article by
Kirstie Pickering

10th June 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics